{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:08Z","timestamp":1786119668862,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11]]},"DOI":"10.1097\/icu.0b013e32833f00b3","type":"journal-article","created":{"date-parts":[[2010,9,9]],"date-time":"2010-09-09T06:18:01Z","timestamp":1284013081000},"page":"473-477","source":"Crossref","is-referenced-by-count":15,"title":["Future for biological therapy for uveitis"],"prefix":"10.1097","volume":"21","author":[{"given":"James T","family":"Rosenbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210206","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.ophtha.2006.04.038","article-title":"Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation","volume":"113","author":"Galor","year":"2006","journal-title":"Ophthalmology"},{"key":"R2-12-20210206","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"R3-12-20210206","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"R4-12-20210206","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"R5-12-20210206","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1001\/archophthalmol.2009.141","article-title":"Infliximab therapy for refractory uveitis: 2-year results of a prospective trial","volume":"127","author":"Suhler","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R6-12-20210206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/bjo.2006.103721","article-title":"Adalimumab in the therapy of uveitis in childhood","volume":"91","author":"Biester","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R7-12-20210206","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/art.21197","article-title":"Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the antitumor necrosis factor agents infliximab and etanercept","volume":"52","author":"Braun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R8-12-20210206","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.2008.092585","article-title":"Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R9-12-20210206","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/art.23835","article-title":"Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action","volume":"59","author":"Collamer","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R10-12-20210206","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","article-title":"Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature","volume":"14","author":"Taban","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R11-12-20210206","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R12-12-20210206","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1212\/WNL.57.10.1885","article-title":"Onset of multiple sclerosis associated with anti-TNF therapy","volume":"57","author":"Sicotte","year":"2001","journal-title":"Neurology"},{"key":"R13-12-20210206","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.ophtha.2009.12.011","article-title":"Intravitreal adalimumab for refractory uveitis-related macular edema","volume":"117","author":"Androudi","year":"2010","journal-title":"Ophthalmology"},{"key":"R14-12-20210206","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"R15-12-20210206","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000103239","article-title":"Rituximab as a treatment option for refractory endogenous anterior uveitis","volume":"39","author":"Tappeiner","year":"2007","journal-title":"Ophthalmic Res"},{"key":"R16-12-20210206","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3109\/s10165-008-0057-9","article-title":"Treatment of retinal vasculitis in Beh\u00e7et's disease with rituximab","volume":"18","author":"Sadreddini","year":"2008","journal-title":"Mod Rheumatol"},{"key":"R17-12-20210206","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2007.133173","article-title":"Rituximab for treatment of ocular inflammatory disease: a series of four cases","volume":"93","author":"Kurz","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"R18-12-20210206","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24454","article-title":"Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis","volume":"60","author":"Taylor","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R19-12-20210206","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/art.24906","article-title":"Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis","volume":"60","author":"Fleischmann","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R20-12-20210206","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2174\/187152009789735071","article-title":"Local treatment for lymphoid malignancies of the eye","volume":"9","author":"Giuliari","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"R21-12-20210206","first-page":"5","article-title":"Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H","volume":"79","author":"Isaacs","year":"1054-","journal-title":"Br J Ophthalmol"},{"key":"R22-12-20210206","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"223 Trial Investigators, Coles AJ, Compston DA, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-12-20210206","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1177\/112067210901900417","article-title":"Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up","volume":"19","author":"Cervantes-Casta\u00f1eda","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R24-12-20210206","doi-asserted-by":"crossref","first-page":"303e2","DOI":"10.1016\/j.ajo.2009.03.028","article-title":"Ranibizumab for refractory uveitis-related macular edema","volume":"148","author":"Acharya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R25-12-20210206","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/acr.20115","article-title":"Abatacept for severe anti-TNFalpha refractory juvenile idiopathic arthritis-related uveitis","volume":"62","author":"Zulian","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R26-12-20210206","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"R27-12-20210206","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJM200304173481614","article-title":"Natalizumab for relapsing multiple sclerosis","volume":"348","author":"Chaudhuri","year":"2003","journal-title":"N Engl J Med"},{"key":"R28-12-20210206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1179\/016164106X98189","article-title":"Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis","volume":"28","author":"Bennett","year":"2006","journal-title":"Neurol Res"},{"key":"R29-12-20210206","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2133.2008.08673.x","article-title":"Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials","volume":"159","author":"Brimhall","year":"2008","journal-title":"Br J Dermatol"},{"key":"R30-12-20210206","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R31-12-20210206","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"R32-12-20210206","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1474-4422(08)70173-X","article-title":"Repeated subcutaneous injections of IL12\/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study","volume":"7","author":"Segal","year":"2008","journal-title":"Lancet Neurol"},{"key":"R33-12-20210206","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"R34-12-20210206","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1084\/jem.20071258","article-title":"Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category","volume":"205","author":"Luger","year":"2008","journal-title":"J Exp Med"},{"key":"R35-12-20210206","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2008.12.019","article-title":"Interleukin-17 causes neutrophil mediated inflammation in ovalbumin-induced uveitis in DO11. 10 mice","volume":"46","author":"Zhang","year":"2009","journal-title":"Cytokine"},{"key":"R36-12-20210206","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N Engl J Med"},{"key":"R37-12-20210206","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/art.27334","article-title":"LY2439821, a humanized antiinterleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"62","author":"Genovese","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R39-12-20210206","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R40-12-20210206","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0161-6420(02)01932-2","article-title":"Treatment of ocular inflammatory disorders with daclizumab","volume":"110","author":"Papaliodis","year":"2003","journal-title":"Ophthalmology"},{"key":"R41-12-20210206","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R42-12-20210206","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/art.20033","article-title":"Spectrum of clinical features in Muckle\u2013Wells syndrome and response to anakinra","volume":"50","author":"Hawkins","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R43-12-20210206","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1056\/NEJMoa063842","article-title":"Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412","volume":"355","author":"Suntharalingam","year":"2006","journal-title":"N Engl J Med"},{"key":"R44-12-20210206","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1167\/iovs.08-2372","article-title":"Efficient intraocular penetration of topical anti-TNF-{alpha} single-chain antibody (ESBA 105) to anterior and posterior segment without penetration enhancer","volume":"50","author":"Ottiger","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e32833f00b3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:42:34Z","timestamp":1786041754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-201011000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e32833f00b3","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11]]}}}